Arrowhead Pharmaceuticals, INC Form 4 insider transactions

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock for $200,000 through a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold shares of common stock between April 9th and April 11th, 2025, to cover taxes associated with the vesting of restricted stock awards.

Arrowhead Pharmaceuticals' CEO, Christopher Anzalone, reports the acquisition of 340,000 shares and the sale of 51,425 shares to cover tax obligations.

Arrowhead Pharmaceuticals' CEO, Christopher Anzalone, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan as the options approached their expiration date.

Christopher Anzalone, CEO of Arrowhead Pharmaceuticals, acquired 9,550 shares of common stock on February 7, 2025, in lieu of a portion of his year-end cash bonus.

Director Douglas S. Ingram acquired 38,396 shares of Arrowhead Pharmaceuticals through restricted stock units that will vest in three years.

A director at Arrowhead Pharmaceuticals, Adeoye Olukotun, sold 959 shares of common stock at $21 per share under a pre-arranged 10b5-1 trading plan.

James Hamilton, Chief Discovery/Trans Medicine at Arrowhead Pharmaceuticals, reported the acquisition of 100,000 shares and the sale of 32,729 shares of common stock.

Arrowhead Pharmaceuticals' COO, Patrick O'Brien, sold a portion of his shares to cover tax obligations after restricted stock units vested, while also selling shares under a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals' Chief Financial Officer, Kenneth Myszkowski, sold a portion of his shares to cover tax obligations after receiving restricted stock units.

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 11,520 shares of common stock on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Adeoye Olukotun, a director at Arrowhead Pharmaceuticals, sold 2,850 shares of common stock at $20 per share on December 27, 2024, under a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 12,563 shares of common stock at an average price of $19.59 on December 23, 2024, to cover tax withholding obligations and pursuant to a pre-arranged 10b5-1 trading plan.

Victoria Vakiener, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock through restricted stock units.

Director Adeoye Olukotun acquired 16,733 shares of Arrowhead Pharmaceuticals through restricted stock units on December 18, 2024.

Director William D. Waddill acquired 16,733 shares of Arrowhead Pharmaceuticals through restricted stock units.

Mauro Ferrari, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock through restricted stock units on December 18, 2024.

Michael Perry, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock through the vesting of restricted stock units.

Director Hongbo Lu of Arrowhead Pharmaceuticals acquired 16,733 shares of common stock through restricted stock units on December 18, 2024.

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold a portion of his shares to cover tax obligations and received new restricted stock units.

A director at Arrowhead Pharmaceuticals, William D. Waddill, sold a total of 7,495 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals director Douglas B. Given sold a total of 5,547 shares of common stock in two transactions on December 16th and 17th, 2024, under a pre-arranged 10b5-1 trading plan.

A director at Arrowhead Pharmaceuticals, Victoria Vakiener, sold 8,994 shares of common stock at an average price of $21.91, as part of a pre-arranged 10b5-1 trading plan.

Tracie Oliver, Chief Commercial Officer of Arrowhead Pharmaceuticals, sold shares of common stock on July 2, 2024, to satisfy tax withholding obligations related to restricted stock units.

Victoria Vakiener, a director of Arrowhead Pharmaceuticals, sold 1,799 shares of common stock at an average price of $23.31 on May 2, 2024, under a pre-arranged 10b5-1 trading plan.

James C. Hamilton, Chief Discovery/Translational Medicine at Arrowhead Pharmaceuticals, sold 6,000 shares of common stock on April 1, 2024, at a weighted average price of $28.03.

Director Hongbo Lu recently purchased 3,000 shares of Arrowhead Pharmaceuticals, increasing his direct holdings in the company.

Kenneth Allen Myszkowski, CFO of Arrowhead Pharmaceuticals, sold 40,000 shares of common stock on March 6, 2024, at an average price of $35.19.